13 articles tagged with "pharmaceuticals"
Following the third Complete Response Letter for Reproxalap, Aldeyra Therapeutics is at a crossroads. This article explores the potential paths forward for the company.
A federal judge has intervened to stop Colorado's initiative to impose a price cap on Enbrel, a major drug produced by Amgen, raising questions about state-level drug pricing regulations.
Recent research suggests that table sugar and vinegar could be used to create affordable carbohydrate-based medicines, potentially replacing expensive treatments for common ailments.
Eli Lilly's obesity drug has garnered significant attention, raising questions about exclusive access and the motivations behind pharmaceutical acquisitions.
As the U.S. observes the situation, European countries are developing varied approaches to drug pricing, which could have significant implications for the pharmaceutical sector and patient access.
Telehealth prescribers are now under heightened scrutiny following FDA warnings about compounded weight loss drugs, while Lilly is actively opposing certain compounding practices.
The FDA has postponed its decision on AstraZeneca's experimental breast cancer pill after an advisory panel voted against its approval, signaling further review is needed.
The pharmaceutical giant Takeda Pharmaceuticals has agreed to a $13.6 million settlement concerning allegations of providing kickbacks to doctors for prescribing its antidepressant.
Pharmaceutical companies have ramped up their lobbying efforts, spending over $130 million in 2025, while Bristol-Myers Squibb has announced a new partnership with a Chinese firm.
The ANSM has imposed sanctions on Novo Nordisk and Eli Lilly for running promotional campaigns disguised as public awareness efforts, raising concerns about ethical advertising practices.
